Background: We evaluated the efficacy and tolerability of a modified biweekly irinotecan, 5-fluorouracil and leucovorin regimen (modified Douillard regimen) as the first-line therapy in patients with advanced colorectal cancer. Methods: A total of 80 patients (41 male, 39 female) with recurrent or metastatic colorectal cancer were enrolled between April 2001 and December 2003. The treatment cycle consisted of irinotecan 150 mg/m 2 as a 90 min infusion on day 1, leucovorin 20 mg/m 2 intravenous bolus, immediately followed by a 48 h continuous infusion of 5-fluorouracil 3000 mg/m 2 on day 1. The primary end-point was response rate, and the secondary end-points were time to progression and toxicity profile. Results: An overall objective response rate of 38.7% [95% confidence interval (CI) 27.84-49.66%] was achieved. The median time to progression was 6.1 months (95% CI 4.63-7.57 months) and the median overall survival time was 20.2 months (95% CI 15.50-24.90 months). The median duration of follow-up for patients was 16.9 months. The toxicity profile was more favorable than for the conventional Douillard regimen. Conclusion: We conclude that the modified Douillard regimen may be a practical and more tolerable treatment option in patients with advanced colorectal cancer.
INTRODUCTION
Colorectal cancer accounts for 10-15% of all cancers and is the second leading cause of cancer deaths in Western countries (1) and the fourth most common cancer in Korea (2) . Although surgery is potentially curative, about one-third of all newly diagnosed patients present with inoperable metastatic disease. Palliative chemotherapy is more effective than the best supportive care in improving survival as well as the quality of life in advanced colorectal cancer (3) . The treatment options for advanced colorectal cancer have been almost exclusively based on 5-fluorouracil (5-FU) and leucovorin (LV) for more than three decades (4) (5) (6) . However, the overall treatment results remain unsatisfactory. Most recently, combination regimens with irinotecan, 5-FU and LV have produced survival benefits superior to 5-FU and LV. In Europe, irinotecan is most frequently combined with an infusional regimen of 5-FU, whereas in the USA bolus 5-FU has been favored until recently. In both regimens, diarrhea and neutropenia were the most common significant adverse events. To reduce diarrhea and neutropenia, we modified the Douillard regimen, and evaluated the efficacy and tolerability of this regimen as the first-line therapy in advanced colorectal cancer patients.
PATIENTS AND METHODS

ELIGIBILITY CRITERIA
To be eligible, patients had to have histologically documented colorectal cancer and at least one measurable lesion according to the World Health Organization (WHO) response criteria; an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2; and adequate bone marrow, hepatic and renal functions. All patients had to be older than 18 years. Prior chemotherapy or radiotherapy for metastatic disease was not permitted; patients who had received adjuvant chemotherapy or concurrent chemoradiotherapy were eligible if they had remained free of disease for at least 6 months after the completion of adjuvant therapy. Written informed consent was required before the start of the chemotherapy.
TREATMENT REGIMEN
On day 1, irinotecan (150 mg/m 2 ) was infused over 90 min, then LV (20 mg/m 2 ) was administered as an intravenous bolus, immediately followed by 5-FU (3000 mg/m 2 ) given as a continuous 48 h infusion. The regimen was repeated every 2 weeks until disease progression or intolerable toxicity was seen or the patient refused further chemotherapy. Toxicities were recorded before each subsequent course was started and graded according to the National Cancer InstituteCommon Toxicity Criteria (NCI-CTC) version 2.0. Any grade 3 or 4 toxic effect resulted in an 20% dose reduction of 5-FU for subsequent cycles. Therapy was delayed in the event of neutrophils <1500/ml, platelets <100 000/ml or persistent diarrhea. Other non-hematological toxicity had to return to at least grade 1 before resuming the next cycle of treatment. Patients were evaluated every 8 weeks (after the completion of four cycles) by computed tomography (CT) scanning for measurable lesions. To prevent nausea and vomiting, a serotonin receptor antagonist was administrated intravenously before chemotherapy and given orally at standard doses after chemotherapy. Atropine was injected subcutaneously before irinotecan administration for the prophylaxis of cholinergic syndrome in all patients. For treatment of delayed diarrhea, loperamide was prescribed after the first loose stool.
RESPONSE AND PROGRESSION CRITERIA
A complete response required that all disease disappeared without new lesions. A partial response required at least a 50% reduction in the sum of the products of the longest perpendicular diameters of all measurable lesions. Progressive disease required >25% increase in measurable lesions or appearance of any new measurable or non-measurable lesion. Patients who did not meet the definitions of response or progression were classified as having stable disease. Time to progression (TTP) was calculated from the first day of the chemotherapy of this study to the date of disease progression. Overall survival (OS) was calculated from the first day of the chemotherapy of this study to the date of death or last contact.
RESULTS
PATIENT CHARACTERISTICS
Eighty patients were enrolled from April 2001 to December 2003. One patient was lost to follow-up, and 79 patients were evaluable for response and toxicity. Patient characteristics are provided in Table 1 . The median age was 60 years (range 18-81 years). Fifty-five patients (67.5%) had their primary disease in the colon and 26 (32.5%) in the rectum. Thirty-four patients (42.5%) had received previous adjuvant chemotherapy or chemoradiation therapy. The most common sites of metastasis were liver, lung and lymph nodes.
RESPONSE TO THERAPY
Among the eighty patients, five patients (6.3%) attained a complete response, and 26 patients (32.5%) achieved a partial response. The overall response rate was 38.7% [31 patients, 95% confidence interval (CI) 25-47%]. Thirty one patients (38.8%) showed stable disease and 17 patients (21.3%) showed progressive disease. Response rates are summarized in Table 2 . A total of 500 courses of chemotherapy were administrated in 80 patients. The median number of cycles was six, ranging from one to 15 cycles. The median follow-up duration was 16.9 months, range 7.9-41.8 months. The median TTP was 6.1 months (95% CI 4.63-7.57 months) and the median OS was 20.2 months (95% CI 15.50-24.90 months).
TOXICITY
The incidence of grade 3-4 toxicities is outlined in Table 3 . Grade 3-4 leukopenia was observed in 17 patients (21.3%), but there was no significant thrombocytopenia and one patient (7) . Irinotecan alone has been shown to be active against both chemotherapy-naïve and 5-FU-refractory patients with advanced colorectal cancer. Data from multicenter studies suggested the survival benefit of irinotecan in patients with 5-FU-refractory metastatic cancer of the colon or rectum (8, 9) . Several phase II studies have shown the survival benefit from the use of irinotecan as a single agent in patients with no prior therapy for advanced colorectal cancer (10, 11) . Many preclinical studies have been performed to explore the possibility of synergistic interactions between 5-FU and irinotecan, and several of the studies confirmed the synergy of this combination in vitro (11) (12) (13) . The mechanism of action of irinotecan generally does not manifest crossresistance with 5-FU when used serially, and the synergistic effect was the rationale for combining irinotecan with 5-FU and LV as a first-line therapy for the disease. Several combination regimens of irinotecan, 5-FU and LV were developed and showed higher rates of tumor regression, progression-free survival and OS without significant toxicity 
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Irinotecan, 5-fluorouracil and leucovorin for advanced colorectal cancer (16) (17) (18) (19) . In Europe, irinotecan is most frequently combined with an infusional regimen of 5-FU, whereas in the USA bolus 5-FU has been favored until recently. No phase III trials directly compared these two regimens, although some reports suggested the equivalent efficacy of the infusional 5-FU and bolus 5-FU, with a lesser toxicity profile in the infusional 5-FU arm (20) . Since the Saltz regimen (5-FU bolus regimen) showed unexpectedly high early death rates, because of gastrointestinal toxicity and thromboembolic events, its safety became the subject of considerable debate (21, 22) . In our dose-modified study, a biweekly infusional schedule was well tolerated and adverse reactions were relatively less than for the conventional infusional schedule. Gastrointestinal toxicity or other adverse reactions were not fatal and grade 3-4 diarrhea was observed in only three patients (3.8%). This result was perhaps due to the low dose of irinotecan (150 mg/m 2 ). The response rate (38.7%) and median TTP (6.1 months) of our study were slightly lower than those of recent studies (18, 19, (23) (24) (25) . Most patients with progressive disease received the second line therapy of oxaliplatin, 5-FU and LV in our study. The median overall survival was 20.2 months, which was comparable with the report of Tournigand et al. (21.5 months) (23) . Fifty-nine patients (73.8%) in our study received the second line chemotherapy of oxaliplatin, 5-FU and LV. The long survival of our patients was probably due to good initial performance status and low initial carcinoembryonic antigen (CEA) level. The comparison of the current study and other randomized phase III studies is summarized in Table 4 .
In conclusion, this phase II study showed that the modified Douillard regimen may be a practical and more tolerable treatment option in patients with advanced colorectal cancer.
